The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | PROs and symptom monitoring in pancreatic cancer care
Annuska Schoorlemmer, Amsterdam UMC, Amsterdam, Netherlands, discusses the integration of patient-reported outcomes (PROs) and symptom monitoring in pancreatic cancer care, highlighting the PACAP study, a nationwide cohort collecting prospective data from patients with pancreatic cancer. She notes that while PRO measurements are used in clinical studies, they are not yet integrated into daily care at the outpatient clinic, which is a goal of the study. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, patient-reported outcome measurements we have in clinical studies, like the PACAP study. It’s a nationwide cohort that collects prospective data from patients with pancreatic cancer. It’s not integrated yet in daily care at the outpatient clinic and we would want to do so, that’s one of the main goals of this study...
Well, patient-reported outcome measurements we have in clinical studies, like the PACAP study. It’s a nationwide cohort that collects prospective data from patients with pancreatic cancer. It’s not integrated yet in daily care at the outpatient clinic and we would want to do so, that’s one of the main goals of this study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
